Carr Patricia 4
4 · Jazz Pharmaceuticals plc · Filed Mar 3, 2025
Insider Transaction Report
Form 4
Carr Patricia
SVP, Chief Accounting Officer
Transactions
- Sale
Ordinary Shares
2025-02-27$144.42/sh−4,500$649,873→ 8,237 total - Sale
Ordinary Shares
2025-02-28$143.29/sh−773$110,767→ 9,485 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-02-27−313→ 0 totalExercise: $123.36Exp: 2026-02-24→ Ordinary Shares (313 underlying) - Exercise/Conversion
Ordinary Shares
2025-02-27$113.10/sh+4,500$508,950→ 12,737 total - Sale
Ordinary Shares
2025-02-27$144.42/sh−313$45,202→ 8,237 total - Award
Ordinary Shares
2025-02-27+2,889→ 10,258 total - Disposition to Issuer
Ordinary Shares
2025-02-27$142.43/sh−371$52,840→ 7,866 total - Disposition to Issuer
Ordinary Shares
2025-02-27$142.43/sh−497$70,788→ 7,369 total - Exercise/Conversion
Ordinary Shares
2025-02-27$123.36/sh+313$38,612→ 8,550 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-02-27−4,500→ 0 totalExercise: $113.10Exp: 2030-02-26→ Ordinary Shares (4,500 underlying)
Footnotes (4)
- [F1]Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F2]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- [F3]These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise.
- [F4]These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise.